Factors influencing macular atrophy growth rates in neovascular age-related macular degeneration treated with ranibizumab or aflibercept according to an observe-and-plan regimen.

CONCLUSION: MA growth rates were associated with ocular factors in the study eyes and the fellow eyes but not with the drug or the number of injections within this variable dosing regimen. PMID: 30166328 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30166328?dopt=Abstract

Source: The British Journal of Ophthalmology - August 30, 2018 Category: Opthalmology Authors: Mantel I, Zola M, De Massougnes S, Dirani A, Bergin C Tags: Br J Ophthalmol Source Type: research